EGFR and non-small cell lung carcinoma: In Australia, EGFR molecular testing is subsidied for testing of tumour tissue from a patient diagnosed with non-small cell lung cancer, shown to have non-squamous histology or histology not otherwise specified to determine EGFR gene status for access to erlotinib or gefitinib.